Clinical outcomes of diabetic foot management with Circulat.
Major and minor lower-extremity amputation is a common complication among diabetics. Various sources indicate diabetic foot ulcer prevalence at between 2.2% and 15% in diabetics. This study evaluates the efficacy and tolerance of a standardized plant extract combination, Circulat, developed for the prevention and treatment of severe manifestations of type 2 diabetes, such as necrotic damage of the foot. Thus, a retrospective cohort study was carried out in 174 patients treated with Circulat with diabetic foot grades D1-D3, according to The University of Texas Wound Classification System, in 50 medical centers, from 2004 to 2007. Circulat obtained 50.57% complete cure of diabetic foot, significant improvement in 37.9% and prevented amputation in 88.5% of the study's total population. The treatment was well tolerated. Four patients (2.3%) had slight gastrointestinal unrest which did not warrant suspension of treatment.
Olalde
J A
JA
Adaptogenic Medical Center, Caracas 1080, Venezuela.
Magarici
M
M
Amendola
F
F
del Castillo
O
O
Gonzalez
S
S
Muhammad
A
A
D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D017719:Diabetic Foot / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D010936:Plant Extracts